Oric Pharmaceuticals, Inc.
ORIC Nasdaq
SEC CIK 1796280
Follow Oric Pharmaceuticals
Weekly email: filings, results
Net income
−$48.1M
−47.5% vs same quarter last year
EPS, diluted
−$0.44
−33.3% vs same quarter last year
Operating cash flow
−$42M
−67.2% vs same quarter last year
Operating income
−$51.6M
−40.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$129.5M |
| FY24 | −$127.8M |
| FY23 | −$100.7M |
| FY22 | −$89.1M |
| FY21 | −$78.7M |
| FY20 | −$73.7M |
| FY19 | −$26.9M |
| FY18 | −$21.4M |
| FY17 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$111.7M |
| FY24 | −$113.9M |
| FY23 | −$86.5M |
| FY22 | −$77.2M |
| FY21 | −$60.5M |
| FY20 | −$45.9M |
| FY19 | −$24.3M |
| FY18 | −$21.2M |
| FY17 | - |